You are here

Bioiberica guarantees that its sodium heparin will comply with the new parameters of the European Pharmacopeia

10 Jun 2013

Bioiberica participated in two studies to establish the standard ranges of activity of Anti-factor Xa and anti-IIa of sodium heparin organized by EDQM, which will be included in the new revision of the monograph of the European Pharmacopoeia.

The results obtained with our product perfectly fit within the new established range. Therefore, we can guarantee that our sodium heparin will comply without any problem with the new parameters of the Pharmacopoeia.

Additionally Bioiberica wishes to inform its customers that the most relevant tests required for certification of the new EP have been performed with its sodium heparin  and we can announce that we are prepared for the upcoming changes.

Related News

28 Sep 2021

The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by

4 Aug 2021
  • Bioiberica produces 20% of the world's Heparin API.
  • Heparin saves around a hundred million lives every year.
  • One out of every 5 doses of heparin administered in the world comes from Bioiberica.
2 Aug 2021
  • One of every 5 doses of heparine administered in the world comes from Bioiberica.
  • Several studies indicate that people hospitalized treated with anticoagulants, improved their chances of survival.